Feel Therapeutics, a San Francisco, CA-based developer of digital biomarkers and therapeutics, raised an undisclosed amount in funding.
SeedtoB Capital made the investment.
The company intends to use the funds to accelerate their progress on the path to making data-driven mental health interventions accessible to those who need them.
Led by CEO George Eleftheriou, Feel Therapeutics is developing digital biomarkers and therapeutics to bring objective data and measurement to diagnose, manage, and care for mental health.
Its data-driven digital therapeutic platform is aimed at patients with Major Depressive Disorder and/or Generalized Anxiety Disorder, and delivers real-time interventions informed by cognitive behavioral therapy frameworks. It can be used as a standalone tool or combined with Feel Therapeutics’ proprietary emotion sensor, a wristband that incorporates affective computing to continuously monitor a user’s emotional state. The platform offers a scalable way to deliver personalized coaching and evidence-based tools that support positive behavioral shifts among users. The solution is accessible via smartphone, addressing challenges around accessibility and delayed intervention that have historically affected individuals struggling with mental health concerns. The platform is currently available to user groups across the United States and Europe, via Feel’s partnerships with select insurance providers and pharmaceutical companies.
Their mental health solutions include:
- Feel Relief, a monthly digital subscription to reduce stress, promote sleep, and improve emotional wellbeing,
- Feel Program, a mental health patient support program combined with remote health monitoring, and
- Feel DTx, the world’s first data-driven digital therapeutic to treat patients with Major Depressive Disorder (MDD) and/or Generalized Anxiety Disorder (GAD) through digital cognitive behavioral therapy (CBT), a health coach, and on-time interventions to deliver 24/7/365 mental health support to those at their point of need.
FinSMEs
06/06/2022